renal tumor
Conditions
Interventions
experimental group:VRDS 4D medical imaging technology
Sponsors
The First Affiliated Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Unlimited gender, aged >= 18 years; non-pregnant or lactating women, and obtain informed consent from the patient or his legal representative; 2. Patients diagnosed with endogenous tumors, renal hilar tumors and renal pelvic tumors who require surgical treatment should be examined by routine CT+VRDS color imaging technique; (the control group only needs to perform routine CT examination); 3. Puncture before treatment is clearly RCC; 4. No other surgical treatment was performed before the surgical treatment and there were no surgical contraindications; 5. ECOG = 12 weeks, follow-up compliance is good; 6. The normal bone marrow reserve function and normal liver function were performed in the following laboratory tests before surgery, which proved that the patient's bone marrow and liver function met the requirements of the study: Absolute white blood cell >= 2.5x10^9/L; Hemoglobin > 100 g/L; Total bilirubin level 100x10^9/L; Alanine aminotransferase, aspartate aminotransferase < 2.5xULN. 7. Allowing for low molecular weight heparin treatment, allowing low doses of anticoagulant therapy to maintain central venous patency and prevent deep vein thrombosis.
Exclusion criteria
Exclusion criteria: 1. Patients with advanced tumors with dyscrasia; 2. Can not accept preoperative puncture and can not adhere to surgical treatment; 3. There are surgical contraindications (including outflow, coagulopathy, severe cardiopulmonary insufficiency); 4. Receiving systemic systemic or topical treatment (including chemotherapy, immunotherapy, other drug-targeted therapy, radiofrequency ablation, radiotherapy, cryotherapy or vascular embolization) before surgery; 5. In addition to kidney cancer, there are other active malignant tumor diseases or a history of other malignant tumors within 5 years (excluding basal cell carcinoma and cervical carcinoma in situ after active treatment); 6. HIV patients who have been diagnosed; 7. Seizures or brain metastasis, spinal cord compression or meningeal metastasis (cancerous meningitis); 8. Severe uncontrollable diseases or active infections; 9. Any of the following within 12 months prior to surgery: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, stroke or transient Cerebral ischemic attack. Deep vein thrombosis or pulmonary embolism occurred within 6 months prior to surgery; 10. Participated in other clinical trials within the past 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preoperative diagnosis accuracy;Surgery Success Rate;Renal ischemia time;Introoperative hemorrhage;Partial nephrectomy positive margin rate;Postoprative GFR;Perioperative complication; | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgery Duration;Overall survival;Disease free survival; | — |
Countries
China
Contacts
Public ContactWang Shuo
The First Affiliated Hospital, School of Medicine, Zhejiang University
Outcome results
None listed